Key facts
- This page summarizes Matthew Stanton's Form 4 filing for Generation Bio Co. (GBIO).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 24 Jan 2023, 15:10.
Matthew Stanton - 20 Jan 2023 Form 4 Insider Report for Generation Bio Co. (GBIO)
- Reporting relationship
- CHIEF SCIENTIFIC OFFICER
- Issuer ticker
- GBIO
- Reported as of
- 20 Jan 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 24 Jan 2023, 15:10:47 UTC
- Prior SEC filing
- 18 Jan 2023
- Next SEC filing
- 18 Apr 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jennifer Elliott, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Matthew Stanton filed Form 4 for Generation Bio Co. (GBIO) on 24 Jan 2023.
Change
- Previous filing in this sequence was filed on 18 Jan 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GBIO
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +53,550
- Change %
- Price
- $0.000000
- Shares after
- 53,550
- Date
- 20 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 53,550
- Exercise price
- $4.71
- Footnotes
- F1
GBIO
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +26,775
- Change %
- Price
- $0.000000
- Shares after
- 26,775
- Date
- 20 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 26,775
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
This option was granted on January 20, 2023. The shares underlying the option vest over four years, with 25% of the shares vesting on January 20, 2024 and the remaining shares vesting in equal quarterly installments thereafter.
Footnote F2
Each restricted stock unit represents the right to receive one share of the company's common stock.
Footnote F3
The shares underlying the restricted stock units vest over four years, with 25% of the shares vesting on January 15, 2024 and the remaining shares vesting in equal quarterly installments thereafter.